TOSHIBA
27.8.2020 07:02:11 CEST | Business Wire | Press release
Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has launched three photorelays: “TLP3407SRA ,” “TLP3475SRHA ” and “TLP3412SRHA ,” that are the industry-smallest[1] voltage driven photorelays with an extended operating temperature rating of 125°C.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200826005815/en/
Raising the maximum operating temperature rating from 110°C to 125°C allows the photorelays to be mounted in high temperature areas, and makes it easier to secure required temperature design margins for equipment. The S-VSON4T package has the industry-smallest[1] mounting area of 2.9mm² .This will contribute to reducing PCB size or to increasing the number of photorelays in an existing layout in applications such as semiconductor testers, probe cards and other devices.
Applications
- Semiconductor testers (memory, SoC and LSI, etc.)
- Probe cards
- Burn-in equipment
- Measuring instruments (oscilloscope, data logger, etc.)
Features
- S-VSON4T, the industry’s first[1] packaging with a minimal mounting area and maximum operating temperature of 125°C: Mounting area 2.9mm2 (typ.)
- Low input power consumption drive: 3.3mW[2] (max) @VIN =3.3V (TLP3407SRA)
Main Specifications
(＠Ta =25℃) |
||||
Part number |
||||
Package |
Name |
S-VSON4T |
||
Size typ. (mm) |
2.0×1.45 |
|||
Height typ.(mm) |
1.3 |
|||
Recommended
|
Applied input forward voltage VIN typ. (V) |
3.3 |
3.3 |
3.3 |
Built-in resistance typ. (Ω) |
4000 |
600 |
600 |
|
Absolute maximum ratings |
OFF-state output terminal voltage VOFF (V) |
60 |
60 |
60 |
ON-state current ION (A) |
1 |
0.4 |
0.4 |
|
ON-state current (pulsed) IONP (A) |
3 |
1.2 |
1.2 |
|
Operating temperature Topr (℃) |
-40 to 125 |
|||
Coupled
|
Limited LED current ILIM(LED) max (mA) (@VIN ) |
1
|
- |
- |
Trigger LED current IFT max (mA) |
0.2 |
2 |
2 |
|
Operating voltage VFON max (V) |
3 |
3 |
3 |
|
ON-state resistance RON max (Ω) |
0.3 |
1.5 |
1.5 |
|
Electrical characteristics |
Output capacitance COFF typ. (pF) |
80 |
12 |
20 (max) |
OFF-state current IOFF max (nA) (@VOFF ) |
1 (@50V) |
1 (@50V) |
1 (@50V) |
|
Switching characteristics |
Turn-on time tON max (ms) |
20 |
0.5 |
0.5 |
Turn-off time tOFF max (ms) |
1 |
0.2 |
0.2 |
|
Isolation characteristic |
Isolation voltage BVS min (Vrms) |
500 |
500 |
500 |
Sample Check & Availability |
||||
Notes:
[1] For photorelays where maximum operating temperature rating is 125°C, according to a survey by Toshiba (as of August 25, 2020).
[2] Applied input forward voltage × maximum limited LED current=3.3V×1mA
Follow the link below for more on the new photocouplers.
TLP3407SRA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3407SRA
TLP3475SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3475SRHA
TLP3412SRHA
https://toshiba.semicon-storage.com/info/lookup.jsp?pid=TLP3412SRHA
Follow the link below for more on Toshiba’s photorelay lineup.
https://toshiba.semicon-storage.com/ap-en/semiconductor/product/optoelectronics/photorelay-mosfet-output.html
To check availability of the new products at online distributors, visit:
TLP3407SRA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3407SRA.html
TLP3475SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3475SRHA.html
TLP3412SRHA
https://toshiba.semicon-storage.com/ap-en/semiconductor/where-to-buy/stockcheck.TLP3412SRHA.html
Customer Inquiries:
Optoelectronic Device Sales & Marketing Dept.
Tel: +81-3-3457-3431
https://toshiba.semicon-storage.com/ap-en/contact.html
* Company names, product names, and service names may be trademarks of their respective companies.
* Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.
About Toshiba Electronic Devices & Storage Corporation
Toshiba Electronic Devices & Storage Corporation combines the vigor of a new company with the wisdom of experience. Since becoming an independent company in July 2017, the company has taken its place among the leading general devices companies, and offers its customers and business partners outstanding solutions in discrete semiconductors, system LSIs and HDD.
Its 24,000 employees around the world share a determination to maximize the value of its products, and emphasize close collaboration with customers to promote co-creation of value and new markets. The company looks forward to building on annual sales now surpassing 750-billion yen (US$6.8 billion) and to contributing to a better future for people everywhere.
Find out more about Toshiba Electronic Devices & Storage Corporation at https://toshiba.semicon-storage.com/ap-en/top.html
View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom